Genzyme and Bone Care International Announce Completion of Hart-Scott-Rodino Review

17-Jun-2005

Genzyme Corporation and Bone Care International, Inc. announced that the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the proposed merger of Genzyme and Bone Care.

As announced on May 4, 2005, Genzyme and Bone Care have signed a definitive merger agreement under which Genzyme will acquire Bone Care in an all cash transaction valued at $33.00 per fully diluted share. The transaction remains subject to approval by Bone Care's shareholders at a meeting on June 30, and other customary closing conditions.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance